In our recent studies, we showed that securin is co-expressed with various CSCs markers (CD24, CD34, CD44, CD117, CD133, ALDH1, SSEA4, Oct4, Shh, beta-catenin and LGR5) in normal ovary (NO), benign (BN), borderline (BL) and high grade (HG) ovarian tumors (unpublished observations), suggesting an important role of securin in modulating the CSC population. The gene discussed is CD44; the disease is ovarian neoplasm.